| 1 |
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro, James Zangrilli, Michael E. Wechsler et al. · The Lancet Respiratory Medicine
|
23 Feb 2015 |
1,192 |
| 2 |
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen David Silberstein, David W. Dodick, MARCELO EDUARDO BIGAL et al. · New England Journal of Medicine
Open access |
24 Nov 2017 |
824 |
| 3 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood
Open access |
4 Mar 2014 |
646 |
| 4 |
Animal models of human disease: Challenges in enabling translation
Paul McGonigle, Bruce Ruggeri · Biochemical Pharmacology
|
14 Aug 2013 |
608 |
| 5 |
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
David Price, Anna Rigazio, Jonathan D. Campbell et al. · The Lancet Respiratory Medicine
Open access |
23 Oct 2015 |
602 |
| 6 |
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
David W. Dodick, Stephen David Silberstein, MARCELO EDUARDO BIGAL et al. · JAMA
Open access |
15 May 2018 |
587 |
| 7 |
Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities
Karen Deborah Davis et al. · Nature Reviews Neurology
ReviewOpen access |
15 Jun 2020 |
512 |
| 8 |
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Michel D. Ferrari, Hans‐Christoph Diener, Xiaoping Ning et al. · The Lancet
|
16 Aug 2019 |
445 |
| 9 |
Drug repurposing from the perspective of pharmaceutical companies
Yoonjeong Cha, T. Erez, Ian J. Reynolds et al. · British Journal of Pharmacology
Open access |
29 Mar 2017 |
440 |
| 10 |
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
Leif Bjermer, Catherine Lemière, Jorge Fernando Maspero et al. · CHEST Journal
Open access |
4 Apr 2016 |
431 |
| 11 |
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease
Huntington Study Group et al. · JAMA
Open access |
5 Jul 2016 |
404 |
| 12 |
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma
Jonathan Corren, Steven F. Weinstein, Lindsay Janka et al. · CHEST Journal
Open access |
25 Mar 2016 |
390 |
| 13 |
Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery
Bruce Ruggeri, Faye Camp, Sheila J. Miknyoczki · Biochemical Pharmacology
|
28 Jun 2013 |
371 |
| 14 |
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial
Karen Elta Anderson, David A. Stamler, Mat D. Davis et al. · The Lancet Psychiatry
|
28 Jun 2017 |
337 |
| 15 |
Anxiety and depression symptoms and migraine: a symptom-based approach research
Mário Fernando Prieto Peres, Juliane Prieto Peres Mercante, Patrícia Renovato Tobo et al. · The Journal of Headache and Pain
Open access |
21 Mar 2017 |
308 |
| 16 |
Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review
Sheela Kolluri, Jianchang Lin, Rachael Liu et al. · The AAPS Journal
Open access |
4 Jan 2022 |
303 |
| 17 |
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
MARCELO EDUARDO BIGAL, David W. Dodick, Alan M. Rapoport et al. · The Lancet Neurology
|
2 Oct 2015 |
288 |
| 18 |
Recent Advances in Lipid-Based Vesicles and Particulate Carriers for Topical and Transdermal Application
Shashank Sharma B. C. Jain, Niketkumar Patel, Mansi K. Shah et al. · Journal of Pharmaceutical Sciences
|
16 Nov 2016 |
283 |
| 19 |
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
MARCELO EDUARDO BIGAL, Lars IH Edvinsson, Alan M. Rapoport et al. · The Lancet Neurology
|
2 Oct 2015 |
264 |
| 20 |
Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations
Ann Taylor et al. · Pain
Open access |
7 Apr 2016 |
215 |
| 21 |
Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea
Samuel Frank et al. · JAMA Neurology
Open access |
10 Jul 2017 |
213 |
| 22 |
Clinical, humanistic, and economic burden of osteoarthritis among noninstitutionalized adults in the United States
Xiaohui Zhao, Drishti Shah, Kavita Gandhi et al. · Osteoarthritis and Cartilage
Open access |
9 Jul 2019 |
182 |
| 23 |
Long-term safety, tolerability, and efficacy of fremanezumab in migraine
Peter James Goadsby, Stephen David Silberstein, Paul P. Yeung et al. · Neurology
Open access |
11 Sep 2020 |
179 |
| 24 |
The First Frontier: Digital Biomarkers for Neurodegenerative Disorders
Earl Ray Dorsey, Spyros Papapetropoulos, Mulin Xiong et al. · Digital Biomarkers
Open access |
4 Jul 2017 |
171 |
| 25 |
Individual-specific functional connectivity of the amygdala: A substrate for precision psychiatry
Chad M. Sylvester et al. · Proceedings of the National Academy of Sciences
Open access |
3 Feb 2020 |
150 |
| 26 |
Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS ‐mutant relapsed or refractory myeloid malignancies
Gautam M. Borthakur et al. · Cancer
Open access |
18 Mar 2016 |
145 |
| 27 |
Research design considerations for chronic pain prevention clinical trials
Jennifer S. Gewandter et al. · Pain
Open access |
16 Apr 2015 |
145 |
| 28 |
Determining incidence of extended spectrum β-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001–2002
Sam K. Bouchillon, Brian M Johnson, D. Hoban et al. · International Journal of Antimicrobial Agents
|
13 Jul 2004 |
141 |
| 29 |
DNA Triplet Repeat Expansion and Mismatch Repair
Ravi R. Iyer, Anna Pluciennik, Марек Напиерала et al. · Annual Review of Biochemistry
ReviewOpen access |
12 Jan 2015 |
134 |
| 30 |
The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
Stephen D. Silberstein, Joshua M. Cohen, Michael J. Seminerio et al. · The Journal of Headache and Pain
Open access |
21 Sep 2020 |
132 |
| 31 |
Recent Advances in Amorphous Solid Dispersions: Preformulation, Formulation Strategies, Technological Advancements and Characterization
Srushti M. Tambe, Divya D. Jain, Saikishore Meruva et al. · Pharmaceutics
Open access |
16 Oct 2022 |
127 |
| 32 |
Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils
Guy Brusselle, Matthew Germinaro, Sivan Weiss et al. · Pulmonary Pharmacology & Therapeutics
Open access |
31 Jan 2017 |
126 |
| 33 |
Digital Health Technology in Asthma: A Comprehensive Scoping Review
Giselle S Mosnaim, GUILHERME G SAFIOTI, Randall W. Brown et al. · The Journal of Allergy and Clinical Immunology In Practice
Open access |
27 Feb 2021 |
120 |
| 34 |
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
Fumihiko Sakai, Norihiro Suzuki, Byung‐Kun Kim et al. · Headache The Journal of Head and Face Pain
Open access |
Jul 2021 |
116 |
| 35 |
Selection of optimal reference genes for normalization in quantitative RT-PCR
Inna Chervoneva, Yanyan Li, Stephanie M. Schulz et al. · BMC Bioinformatics
Open access |
14 May 2010 |
115 |
| 36 |
Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors
Thelma S. Angeles, Robert L. Hudkins · Expert Opinion on Drug Discovery
|
5 Oct 2016 |
114 |
| 37 |
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
Ralf Reilmann et al. · The Lancet Neurology
120 authors |
15 Dec 2018 |
112 |
| 38 |
Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System
Nádia Araci Bou‐Chacra, Katherine Jasmine Curo Melo, Ivan Andrés Cordova Morales et al. · The AAPS Journal
Open access |
17 May 2017 |
110 |
| 39 |
Comparison of the size and morphology of UHMWPE wear debris produced by a hip joint simulator under serum and water lubricated conditions
A. Wang, Aaron Essner, C Stark et al. · Biomaterials
|
1996 |
110 |
| 40 |
Application of Melt Granulation Technology to Enhance Tabletting Properties of Poorly Compactible High-Dose Drugs
Jay P. Lakshman, James Kowalski, Madhav Vasanthavada et al. · Journal of Pharmaceutical Sciences
|
3 Dec 2010 |
106 |
| 41 |
Therapeutic antibodies against CGRP or its receptor
MARCELO EDUARDO BIGAL, Sarah J. Walter, Alan M. Rapoport · British Journal of Clinical Pharmacology
Open access |
23 Jan 2015 |
106 |
| 42 |
Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease
Daniel O. Claassen, Benjamin Carroll, Lisa M. De Boer et al. · Journal of Clinical Movement Disorders
Open access |
15 Feb 2017 |
105 |
| 43 |
Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims
Benjamin J. Chastek, MerriKay A. Oleen-Burkey, Maria V. Lopez-Bresnahan · Journal of Medical Economics
Open access |
Oct 2010 |
105 |
| 44 |
Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
Fumihiko Sakai, Norihiro Suzuki, Byung‐Kun Kim et al. · Headache The Journal of Head and Face Pain
Open access |
Jul 2021 |
103 |
| 45 |
Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine
Stephen David Silberstein, Lulu Lee, Kavita Gandhi et al. · Headache The Journal of Head and Face Pain
|
30 Oct 2018 |
103 |
| 46 |
Inspiring process innovation via an improved green manufacturing metric: iGAL
Frank Roschangar et al. · Green Chemistry
|
2018 |
103 |
| 47 |
2 Discovery of Cep-1347/Kt-7515, an Inhibitor of the Jnk/Sapk Pathway for the Treatment of Neurodegenerative Diseases
Michael S. Saporito, Robert L. Hudkins, Anna Coco Maroney · Progress in medicinal chemistry
Book chapter |
2002 |
98 |
| 48 |
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019
William G. Wierda et al. · Journal of the National Comprehensive Cancer Network
|
2019 |
95 |
| 49 |
Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations
Maciej Ga̧sior, Mary Lou Bond, Richard I. Malamut · Postgraduate Medicine
Open access |
13 Nov 2015 |
93 |
| 50 |
Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)
Gregory R. Ott et al. · Journal of Medicinal Chemistry
Open access |
15 Aug 2016 |
92 |